Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Special protocol assessment process for the dipeptidyl peptidase inhibitor would have delayed start of Phase III non-small cell lung cancer trials, exec says.